BidaskClub cut shares of Agenus (NASDAQ:AGEN) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

Other research analysts also recently issued reports about the company. Zacks Investment Research raised Agenus from a sell rating to a hold rating in a report on Thursday. ValuEngine raised Agenus from a hold rating to a buy rating in a report on Thursday, January 17th.

Shares of NASDAQ:AGEN opened at $3.50 on Friday. The firm has a market cap of $419.99 million, a PE ratio of -2.85 and a beta of 1.98. Agenus has a 1 year low of $1.54 and a 1 year high of $6.19.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.04). The firm had revenue of $12.80 million during the quarter, compared to analysts’ expectations of $10.76 million. On average, analysts predict that Agenus will post -1.35 EPS for the current year.

Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agenus by 272.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,105 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 23,493 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Agenus during the second quarter valued at $101,000. Virtu Financial LLC bought a new position in shares of Agenus during the third quarter valued at $105,000. Jefferies Group LLC lifted its holdings in shares of Agenus by 171.2% during the third quarter. Jefferies Group LLC now owns 166,523 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 105,123 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Agenus by 9.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock valued at $870,000 after purchasing an additional 34,065 shares in the last quarter. 31.73% of the stock is currently owned by hedge funds and other institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Further Reading: Are 12b-1 Fees Affecting Your Mutual Fund Performance?

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.